本文選題：冬腎丸　切入點(diǎn)：IgA腎病　出處：《湖南中醫(yī)藥大學(xué)》2016年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：目的:本文主要是通過(guò)對(duì)冬腎丸治療IgA腎病氣陰兩虛證患者的臨床療效觀(guān)察,評(píng)估其用藥價(jià)值及臨床推廣用藥,改善患者臨床癥狀,延緩其腎功能進(jìn)展,提升患者生存質(zhì)量。方法:將符合西醫(yī)IgA腎病診斷標(biāo)準(zhǔn)和氣陰兩虛證中醫(yī)辯證標(biāo)準(zhǔn)的40例患者隨機(jī)分成治療組20例、對(duì)照組20例,治療組口服冬腎丸、觀(guān)察組口服纈沙坦,總療程為8周,其后觀(guān)察其治療前后的尿紅細(xì)胞數(shù)、24小時(shí)尿蛋白定量、腎功能、中醫(yī)證候等方面的變化及不良反應(yīng),評(píng)估其用藥效果。結(jié)果:冬腎丸組和纈沙坦組兩組治療前均無(wú)統(tǒng)計(jì)學(xué)差異,具有齊同可比性。兩組臨床療效和臨床癥狀治療前后對(duì)比,冬腎丸組總有效率為90(90)%,而纈沙坦組總有效率為70(75)%,從兩組總有效率來(lái)看表明兩者治療均有效,然兩組組間進(jìn)行比較冬腎丸組明顯優(yōu)于纈沙坦組,差異有統(tǒng)計(jì)學(xué)意義(p0.05);兩組在改善尿紅細(xì)胞數(shù)、24小時(shí)尿蛋白方面冬腎丸組優(yōu)于纈沙坦組(p0.05);兩組中醫(yī)證候總積分方面冬腎丸組和纈沙坦組較前均有下降,組間對(duì)比治療組優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(p0.01)。結(jié)論:冬腎丸與纈沙坦均能改善患者癥狀、體征及生化指標(biāo),且兩組間的比較顯示冬腎丸組明顯優(yōu)于纈沙坦組,對(duì)于氣陰兩虛型的IgA腎病患者療效突出,且無(wú)不良反應(yīng),值得進(jìn)一步推廣及臨床用藥。
[Abstract]:Objective: to evaluate the clinical efficacy of Dongshen pills in the treatment of IgA nephropathy with deficiency of qi and yin, to improve the clinical symptoms and delay the progress of renal function. Methods: 40 patients with IgA nephropathy and Qi-Yin deficiency syndrome were randomly divided into treatment group (n = 20) and control group (n = 20). The total course of treatment was 8 weeks. After the treatment, the changes and adverse reactions of urinary erythrocyte count in 24 hours urine protein quantity, renal function, TCM syndromes and other aspects were observed. Results: there was no statistical difference between the two groups before treatment and there was no comparison between the two groups. The clinical efficacy and symptoms of the two groups were compared before and after treatment. The total effective rate of Dongshen Pill group was 90%, while that of Valsartan group was 700.The total effective rate of the two groups showed that both groups were effective. However, compared between the two groups, the Dongshen pills group was obviously superior to the valsartan group, and the total effective rate of the two groups was higher than that of the valsartan group. There was significant difference between the two groups in improving urine erythrocyte count and 24 hours urine protein, the two groups were superior to valsartan group in improving the urine protein of 24 hours, the total integral of TCM syndromes of the two groups were lower than that of the previous group, the total score of TCM syndromes of the two groups was lower than that of the previous group, and there was no significant difference between the two groups in the total score of TCM syndromes. Conclusion: both Dongshen pills and valsartan can improve the symptoms, signs and biochemical indexes of the patients, and the comparison between the two groups shows that the Dongshen pills group is obviously superior to the valsartan group. For the patients with IgA nephropathy with deficiency of qi and yin, the curative effect is outstanding and no adverse reactions. It is worthy of further promotion and clinical use.
【學(xué)位授予單位】：湖南中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R277.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張琳;曹式麗;;曹式麗從毒論治IgA腎病經(jīng)驗(yàn)[J];遼寧中醫(yī)雜志;2015年12期

2 耿嘉;王今朝;;不同中醫(yī)證候IgA腎病患者腎組織FoxP_3的表達(dá)及其相關(guān)分析[J];中國(guó)中醫(yī)藥科技;2015年04期

3 茍中富;;張玉龍治療IgA腎病學(xué)術(shù)經(jīng)驗(yàn)擷要[J];四川中醫(yī);2015年07期

4 車(chē)妙琳;湯璐敏;車(chē)琳;林星輝;顧樂(lè)怡;沈惠風(fēng);嚴(yán)玉澄;;IgA腎病中醫(yī)辨證與牛津病理關(guān)系108例臨床分析[J];疑難病雜志;2015年05期

5 邵命海;卓鵬偉;彭培初;;彭培初辨治IgA腎病經(jīng)驗(yàn)探析[J];上海中醫(yī)藥雜志;2015年04期

6 巴元明;林曉媛;;邵朝弟治療IgA腎病的經(jīng)驗(yàn)[J];時(shí)珍國(guó)醫(yī)國(guó)藥;2015年03期

7 孟嫣;常崢;孟元;蔡朕;張勝容;;益氣養(yǎng)腎湯治療IgA腎病氣陰兩虛證臨床研究[J];中國(guó)中西醫(yī)結(jié)合腎病雜志;2015年02期

8 陳峰;劉學(xué)永;甘志洲;陳曉明;;黃芪注射液穴位注射治療IgA腎病蛋白尿的臨床研究[J];河北中醫(yī);2014年12期

9 姜飛;俞東容;蔡麗麗;;IgA腎病預(yù)后危險(xiǎn)因素研究進(jìn)展[J];中國(guó)中西醫(yī)結(jié)合腎病雜志;2014年11期

10 賈冕;梁貽俊;;梁貽俊治療IgA腎病經(jīng)驗(yàn)[J];中醫(yī)雜志;2014年22期

，

本文編號(hào)：1583488